Multiple Myeloma Clinical Trial
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Full Description
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
Eligibility Criteria
Inclusion Criteria:
Participants must agree to follow the reproductive criteria as outlined in the protocol
Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Exclusion Criteria:
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 12 Locations for this study
Orange California, 92868, United States
Indianapolis Indiana, 46237, United States
Melbourne Victoria, 3002, Australia
Richmond Victoria, 3121, Australia
Richmond Victoria, 3121, Australia
Calgary Alberta, T2N 4, Canada
Edmonton Alberta, T6G 1, Canada
Montréal Quebec, H4A 3, Canada
Pierre-Bénite Rhône, 69310, France
Paris , 75010, France
Nagoya Aichi, 467-8, Japan
Kobe Hyogo, 650-0, Japan
Sendai-shi Miyagi, 980-8, Japan
How clear is this clinincal trial information?